Turbulencia empresarial en Colombia : sector de seguros

En el año 2010, la Facultad de Administración de la Universidad del Rosario puso en marcha un proyecto de investigación donde se exploraba el fenómeno de la turbulencia empresarial. En este momento han sido publicados más de 15 documentos donde se realiza la descripción de lo ocurrido en igual número de sectores. En este número se realiza un análisis del sector asegurador, actividad empresarial que contribuye de manera significativa a la economía del país. El trabajo ha sido realizado de manera conjunta por los profesores Natalia Malaver y Hugo Rivera de la asignatura Estrategia de empresa I, con estudiantes del pregrado de la Facultad, quienes se motivaron por encontrar respuestas a la forma como algunas empresas del sector enfrentan la turbulencia sectorial. La estructura del documento incluye una breve descripción del sector; luego un análisis de la turbulencia, y un estudio sectorial realizado aplicando la metodología del Análisis Estructural de Sectores Estratégicos (AESE) desarrollada por el grupo de investigación en perdurabilidad empresarial de la Facultad de Aministración de la Universidad del Rosario

Expanded parameters to assess the quality of honey from Venezuelan bees (Apis mellifera).

Hive samples from seven Venezuelan states were studied to determine the quality of honeys from the naturalized tropical honey bee Apis mellifera, submitted for a national honey competition. The physicochemical composition varied as follows: antibacterial activity as minimal inhibitory concentration for each of S. aureus and E. coli was 25.0-50.0 g/100 mL, antioxidant activity was 34.90-203.21 ?moles Trolox equivalents/100 g, ash was 0.03-0.13 g/100 g, diastase activity was 3.00-47.81 DN, flavonoids was 2.32-14.41 mg EQ/100 g, free acidity was 24.40-54.55 meq/kg, HMF was 17.70-631.73 mg/kg, moisture content was 17.2-20.2 g/100 g and nitrogen was 28.68-107.29 mg/100 g. Non aromatic organic acids, such as D-gluconic acid, was 13.5-69.3 g/kg, citric acid was 8.0-135.4 mg/kg, and malic acid was 11.2-60.9 mg/kg. Polyphenols were 38.15-182.10 mg EGA/100g, reducing sugars were 62.05-77.57 g/100 g, sucrose was 0.93-13.86 g/100 g, and vitamin C was 12.86-37.05 mg/100 g. Botanical origins of the nine honeys, determined by pollen analysis, indicate that these honeys often were derived from non-forest, non-native and weedy species. The results are a first step to better characterisation of honeys, and some of the parameters were determined for the first time in Venezuelan A. mellifera honey. They can be used for research, educational purposes, and to better understand market values, natural occurrence and chemistry of tropical honey harvested from Apis mellifera

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome

[Introduction] Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS including all risk categories. Recently, the incorporation of genomic data to clinical parameters defined the new Molecular International Prognostic Scoring System (IPSS-M).[Materials and Methods] In this study, we evaluated the impact of molecular profile in a series of 181 patients with LR-MDS and non-proliferative chronic myelomonocytic leukemia.[Results] Epigenetic regulators (TET2, ASXL1) and splicing (SF3B1) were the most recurrent mutated pathways. In univariate analysis, RUNX1 or TP53 mutations correlated with lower median overall survival (OS). In contrast, SF3B1 mutation was associated with prolonged median OS [95 months (95% IC, 32-157) vs. 33 months (95% CI, 19-46) in unmutated patients (P < 0.01)]. In a multivariate Cox regression model, RUNX1 mutations independently associated with shorter OS, while SF3B1 mutation retained its favorable impact on outcome (HR: 0.24, 95% CI, 0.1-0.5; P = 0.001). In addition, TP53 or RUNX1 mutations were identified as predictive covariates for the probability of leukemic progression (P < 0.001).[Conclusion] Incorporation of molecular testing in LR-MDS identified a subset of patients with expected poorer outcome, either due to lower survival or probability of leukemic progression.Peer reviewe

Ruxolitinib in refractory acute and chronic graft-versus-host disease : a multicenter survey study

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Hacinamiento estratégico, una enfermedad que erosiona la rentabilidad del sector: caso de la industria farmacéutica en Colombia

Las organizaciones en la última década se han enfrentado a un entorno turbulento, caracterizado por un aumento en la complejidad de las relaciones, cambios en las necesidades de los clientes e incremento de la incertidumbre en la toma de decisiones. Algunas empresas para responder a esta situación utilizan las mismas estrategias de los líderes de la industria, lo que lleva a un proceso de convergencia, que afecta la rentabilidad del sector. Este documento presenta una metodología que permite percibir de una mejor manera lo que ocurre en un sector y determinar el grado de convergencia

Efectos del entrenamiento físico aeróbico sobre oxidantes y antioxidantes en saliva de hombres jóvenes sedentarios

Estudios en plasma indican que el ejercicio físico aeróbico incrementa las defensas antioxidantes y reduce el estrés oxidativo en los seres humanos. No obstante, la evidencia respecto al efecto del entrenamiento sobre el estrés oxidativo y la actividad antioxidante en saliva es limitada. OBJETIVO: Examinar el efecto del entrenamiento físico aeróbico sobre la concentración de óxido nítrico, ácido úrico, actividad antioxidante total y estrés oxidativo en saliva de hombres jóvenes sedentarios. MÉTODO: Antes y después de 14 semanas de entrenamiento, 24 hombres no entrenados fueron evaluados. Muestras de saliva se obtuvieron 24 horas, 1 hora antes, e inmediatamente después del ejercicio. La concentración de nitrito se determinó por la reacción de Griess, hidroperóxidos lipídicos por el método de FOX, ácido úrico mediante un kit enzimático y actividad antioxidante total por el método del ABTS. Se empleó un Análisis de Varianza de dos vías con medidas repetidas en ambos factores, entrenamiento y tiempo. Los RESULTADOS: revelaron que inmediatamente después del ejercicio con 24 horas se observo una mayor reducción del estrés oxidativo, al igual que después del entrenamiento en comparación a antes del entrenamiento. El ácido úrico aumentó inmediatamente después del ejercicio antes del entrenamiento, pero se mantuvo constante después del entrenamiento. La concentración de óxido nítrico y la actividad antioxidante total disminuyeron después del entrenamiento en comparación a antes del período de entrenamiento. CONCLUSIÓN: Este estudio en saliva confirma informes en plasma en los que se indica que el entrenamiento reduce el estrés oxidativo en seres humanos

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

On behalf of the Grupo Español de Trasplante Hematopoyético (GETH): et al.Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.This study has been performed in collaboration with the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH). To the CIBERONC (CB16/12/00480).Peer reviewe

Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.

The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR). In a prospective trial, we previously reported a reduction in the incidence of chronic GvHD (cGvHD) among patients who received vit D after allogeneic stem cell transplantation (allo-HSCT; Clinical Trials.gov: NCT02600988). Here we analyze the role of patients and donors' VDR SNPs on the immunomodulatory effect of vit D. Patients undergoing allo-HSCT were included in a prospective phase I/II clinical trial (Alovita) in three consecutive cohorts: control (without vit D), low-dose (1,000 IU/day), and high-dose (5,000 IU/day) groups. Vit D was given from day -5 until +100 after transplant. Genotyping of four SNPs of the VDR gene, FokI, BsmI, ApaI, and TaqI, were performed using TaqMan SNP genotyping assays. We observed a decrease in the incidence of overall cGvHD at 1 year after allo-HSCT depending on the use or not of vit D among patients with FokI CT genotype (22.5% vs 80%, P = 0.0004) and among those patients without BsmI/ApaI/TaqI ATC haplotype (22.2% vs 68.8%, P = 0.0005). In a multivariate analysis, FokI CT genotype significantly influenced the risk of cGvHD in patients treated with vit D as compared with the control group (HR 0.143, Pinteraction Our results show that the immunomodulatory effect of vit D depends on the VDR SNPs, and patients carrying the FokI CT genotype display the highest benefit from receiving vit D after allo-HSCT